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Abstract
Xenobiotic drugs induce Pleiotropic Drug Resistance (PDR) genes via the orthologous Pdr1/Pdr3 transcription activators. We
previously identified the Mediator transcription co-activator complex as a key target of Pdr1 orthologs and demonstrated
that Pdr1 interacts directly with the Gal11/Med15 subunit of the Mediator complex. Based on an interaction between Pdr1
and the FACT complex, we show that strains with spt16 or pob3 mutations are sensitive to xenobiotic drugs and display
diminished PDR gene induction. Although FACT acts during the activation of some genes by assisting in the nucleosomes
eviction at promoters, PDR promoters already contain nucleosome-depleted regions (NDRs) before induction. To determine
the function of FACT at PDR genes, we examined the kinetics of RNA accumulation and changes in nucleosome occupancy
following exposure to a xenobiotic drug in wild type and FACT mutant yeast strains. In the presence of normal FACT, PDR
genes are transcribed within 5 minutes of xenobiotic stimulation and transcription returns to basal levels by 30–40 min.
Nucleosomes are constitutively depleted in the promoter regions, are lost from the open reading frames during
transcription, and the ORFs are wholly repopulated with nucleosomes as transcription ceases. While FACT mutations cause
minor delays in activation of PDR genes, much more pronounced and significant defects in nucleosome repopulation in the
ORFs are observed in FACT mutants upon transcription termination. FACT therefore has a major role in nucleosome
redeposition following cessation of transcription at the PDR genes, the opposite of its better-known function in nucleosome
disassembly.
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Introduction
Fungal disease remains a serious clinical concern, notably in an
increasingly immunocompromised population, and especially
given newly emerging fungal pathogens [1–3]. Drug treatment
using an array of antifungal compounds often becomes ineffectual
due to the ability of pathogens to overproduce membrane-
associated broad-specificity xenobiotic efflux pumps, rendering
them resistant to therapy [4]. These transport proteins are
members of the ubiquitous and diverse ATP Binding Cassette
(ABC) superfamily, which have a broad spectrum of roles in many
phyla, including MDR (Multi-Drug Resistance) in cancer chemo-
therapy, antibiotic, herbicide, and other cytotoxic compound
resistance, as well as in cellular homeostatic processes [5–9]. ABC
members in Saccharomyces cerevisiae are similarly diverse, but the
subset that confers resistance to antifungal toxins are encoded by
the PDR (Pleiotropic Drug Resistance) genes [10–14].
Xenobiotic-induced expression of PDR efflux pump genes is
complex, but is primarily programmed by the zinc-cluster
transcription factor Pdr1 [15–17], along with the orthologous
Pdr3 factor [18,19], which are constitutively bound to PDRE
sequences in PDR promoters, even in the absence of toxin [20].
Gene regulatory cofactors including the histone modifier SAGA
and chromatin remodeler Swi/Snf have been shown to be
recruited to PDR target gene promoters, and implicated in their
activation [20]. Screens for mutations causing greater PDR1-
dependent drug sensitivity have also indicated the HDAC Rpd3L
may have a role in PDR gene activation [21]. Our previous work
demonstrated that Pdr1 is capable of binding directly to
antifungals and other xenobiotics, presumably causing a confor-
mational change liberating the carboxyl-terminal transactivation
domain, which can then productively engage transcription
coactivators [22,23]. We also showed that xenobiotic-activated
Pdr1 promotes recruitment of the Mediator coactivator to the
PDR5 promoter through direct interaction of the KIX domain in
its Gal11 component, and that Gal11 and other modules of
Mediator are necessary for the PDR response in both Saccharomyces
as well as pathogenic Candida yeasts [22,23].
FACT (FAcilitates Chromatin Transcription [24]) is an
abundant, essential, highly conserved chromatin altering factor
in eukaryotes composed of a heterodimer of Spt16 [25] and the
HMG domain containing SSRP1 [26,27] in non-fungal eukary-
otes. In fungi, Spt16 complexes with the SSRP1 truncated
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homolog Pob3 but the HMG domain lies in a separate protein,
Nhp6 [28], that associates with the FACT core supra-stoichio-
metrically [29–31]. Both Spt16 and Pob3 each carry a double
pleckstrin homology (PH) domain as well as other protein binding
domains [32,33]. FACT is able to reorganize the interaction of
DNA with histones in a nucleosomal context in vitro, but in a way
mechanistically different than ATP-dependent remodelers [34].
Lack of FACT function in vivo results in a number of both
replication and transcription phenotypes [31,35–37]. A role for
FACT in transcriptional elongation is supported by its ability to
stimulate transcription through a chromatin barrier in vitro [24],
its association with elongation factors [38,39], and the presence of
FACT at transcribed regions of genes in vivo [40,41]. FACT is
modeled as both disassembling and reassembling nucleosomes
during elongation [42], with the importance of the reassembly role
demonstrated by the observation that FACT mutants activate
cryptic TATA elements because of inadequate restoration of
repressive chromatin following transcription [40,43]. There is also
evidence that FACT regulates transcription initiation by affecting
the accessibility of promoter regions to initiation factors and by
participating in nucleosome eviction [37,44–47]. FACT has
therefore been implicated in both removal and assembly of
nucleosomes prior to and during transcription elongation.
In this study, we demonstrate that efficient activation of PDR
genes requires the chromatin reorganizing complex FACT, and
that yeast defective in FACT function show increased sensitivity to
xenobiotic drugs. PDR genes respond to toxin exposure with a
rapid accumulation of PDR mRNA quickly followed by a
subsequent reduction in transcript levels. This transcriptional
induction and reduction is mirrored by sudden histone loss and
repopulation across PDR loci, which allows direct analysis of
FACT’s effects on chromatin assembly and disassembly in a native
context. PDR gene promoters contain Nucleosome Depleted
Regions (NDRs), and thus FACT is not required for the same
types of chromatin changes that occur at other promoters before
gene activation, although FACT mutations cause minor delays in
activation of PDR genes. Surprisingly, FACT mutants instead
display a marked delay in repopulation of nucleosomes in the
proximal promoter and open reading frame following cessation of
transcription, revealing a novel role of FACT in chromatin
reassembly in the wake of gene transcription.
Materials and Methods
For large-scale purification and identification of GST–Pdr1 AD-
associated proteins, 6 L YPD medium (with 3% dextrose) was
inoculated with yeast at an OD600 of 0.03 and grown at 30uC
with shaking for approximately 13 hours, until an OD600 of ,4.
The cell pellet was then resuspended in 0.25 volumes of lysis buffer
(50 mM Tris-HCl (pH 8.0), 400 mM NaCl, 5 mM MgCl2, 1 mM
EGTA, 1 mM EDTA, 0.1% NP40, 1 mM DTT, 0.25 mM
PMSF, 1 mM benzamidine, 0.5 mg ml-1 aprotinin and Protease
Inhibitor Cocktail (Complete, Roche)), and the suspension was
quick-frozen in liquid nitrogen. Frozen cells were lysed by grinding
with a mortar and pestle together with dry ice. One volume of lysis
buffer was added after evaporation with dry ice, and the extract
was spun at 4,000 g for 10 min. The supernatant was pre-
incubated with 200 ml glutathione–Sepharose-bound GST for 2 h
at 4uC with rotation, then it was incubated for another 3 h at 4uC
with 200 ml glutathione–Sepharose-bound GST–Pdr1-AD (amino
acids 966–1068), expressed and purified as described [22]. The
beads were washed seven times with wash buffer (20 mM Tris-
HCl, pH 8.0, 250 mM KCl, 0.1 mM EDTA, 10% glycerol, 0.1%
NP-40, 5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM DTT,
0.25 mM PMSF, 1 mM benzamidine and Protease Inhibitor
Cocktail). The beads were finally washed once with low salt
(150 mM NaCl) wash buffer. The bound proteins were then eluted
with 500 mL of 0.3% sarkosyl in binding buffer for 1 h at 4uC and
dialyzed overnight in 1 L of dialysis buffer (1% SDS, 1 mM b-
mercaptoethanol and 1 mM Tris-HCl, pH 8.0). The dialyzed
eluate was concentrated by dry-ice/ethanol SpeedVac to approx-
imately 80 ml. The eluted proteins were resolved on 10%
polyacrylamide gel and stained with Coomassie colloidal blue.
Stained proteins were excised and subjected to trypsin digestion,
followed by liquid chromatography MS/MS (LC-MS/MS) at the
Taplin Biological Mass Spectrometry Facility at Harvard Medical
School as previously described (Thakur et al. 2008).
Yeast strains and plasmids are listed in Table S1. For plate spot
dilution growth assays, liquid cultures of the indicated strains at
permissive temperature were grown to saturation, serially diluted
in 10 fold increments, spotted onto YPAD agar media containing
0, 200, or 500 nM Ketoconazole (Sigma), incubated as denoted,
and photographed.
Liquid culture growth rates were measured by diluting stock
cultures grown for 24 hr at 25uC from single colonies in
quadruplicate into fresh YPAD containing 0, 200, or 500 nM
Ketoconazole, and incubating all cultures simultaneously in a
Bioscreen-C Automated Growth Curve Analysis System (Growth
Curves USA, Piscataway, NJ) for 24 hr at the indicated
temperatures. Data consisting of OD600 measurements at
30 min intervals were analyzed and plotted using Prism 6.0c
(GraphPad Software).
For gene expression and ChIP analysis, cells were cultured at
the indicated temperature in 750 mL YPAD for 12–20 hr to a
density of ,16107 cells/mL (OD660 =,0.75). For analysis of
induction of PDR genes, aliquots were collected just prior to, and
every 2.5 to 10 min after addition of Ketoconazole (Sigma) to
40 mM. ChIP samples were prepared by immediately adding
formaldehyde at the designated time to a 50 mL culture aliquot to
1%, rocking at RT for 20 min, adding glycine to 125 mM, and
immediately chilling on ice for 24 hr. Cells were then rinsed by
centrifugation and resuspension twice in 1 volume of PBS, once in
1/50 volume of FA buffer [48], and the pelleted cells were flash
frozen in liquid nitrogen, and stored at 280uC for processing.
For Myc, histone H3, and Spt16 immunoprecipitations,
chromatin was prepared by cell lysis in 750 mL ice-cold ChIP
Lysis Buffer (FA buffer containing 0.1% NP-40, 0.1% SDS, 5 mM
MgCl2, 1 mM DTT, and protease inhibitors), and 1.2 mL pre-
chilled 0.5 mm Zirconia/Silica beads in screw-cap microcentri-
fuge tubes using 6 cycles of 2 min each in a Mini-Bead-Beater 96
(Biospec Products), in a block chilled to 220uC, with 1 min
chilling of the tubes on ice between each cycle. Recovered lysates
were centrifuged 1 hr at 23 K rpm at 0uC, supernatant discarded,
and the crude pellets were rinsed by partial resuspension in ice-
cold 750 mL ChIP Lysis Buffer, and spun again for 15 min. For
sonication, pellets were thoroughly resuspended with gentle probe
sonication in fresh ChIP Lysis Buffer at 0uC, and chromatin was
sheared by 60 cycles of a 30 sec burst followed by a 60 sec rest in a
Bioruptor XL (Diagenode) at high power with circulating chilled
water at 2uC. Debris was pelleted by centrifugation for 5 min at
23 K rpm at 0uC, and the soluble chromatin supernatant was
aliquoted on ice, flash frozen in liquid nitrogen, and stored at
280uC. Chromatin shearing adequate for fine resolution analysis
was confirmed by DNA gel electrophoresis of de-crosslinked and
purified samples, and showed that the average fragment lengths
were approximately 200 bp.
ChIP was carried out using 1 mg affinity purified anti-histone
H3 C-terminus or anti-Myc (Mouse MAb 4A6, Upstate Biotech-
Repopulation of Nucleosomes by FACT
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nology) or 5 mL anti–Spt16 serum rabbit polyclonal antibodies
(Tim Formosa, University of Utah) pre-bound to approximately
36107 anti-Rabbit IgG-coated magnetic beads (Invitrogen) per
reaction. Immunoprecipitations contained chromatin with 500 mg
protein content measured by BCA assay, beads, 1.5 mg/mL BSA,
all in ChIP Lysis buffer as above, except with 0.01% SDS and
0.5 mM MgCl2 instead. Beads were washed for 5 min at 4uC
twice with ChIP Lysis buffer as above, except with no SDS, twice
with ChIP Lysis buffer as above, except with 500 mM NaCl and
no SDS, and twice with ChIP Wash Buffer [48]. ChIP reactions
were eluted from beads and de-crosslinked using Chelex-100
according to [49]. Aliquots of each input total chromatin
corresponding to 25 mg protein content were de-crosslinked in
parallel. Occupancy was measured by qPCR using primers for the
indicated target and reference locations. SYBR-Green containing
qPCR reactions with 1/4th to 1/20th dilution of the ChIP reaction
and 1/200th to 1/1000th dilution of the input total chromatin were
carried out in a Lightcycler LC480 (Roche), and were then
quantified by also preparing a dilution set of the input total
chromatin reactions analyzed in parallel to generate a standard
curve, and calculating each target’s relative concentration from the
reaction’s Cq using the manufacturer software. Levels of
occupancy were compared between samples by first calculating a
ChIP signal by dividing the relative concentration of a target in the
ChIP reaction by that of the input chromatin to obtain a fraction
or % IP value, then normalizing each ChIP signal to that for the
IGR-I gene-free reference region on chromosome I [50]. Error
bars for each point represent the propagated error from two to
three PCR reactions each for the target sequence in the ChIP
reaction and input, as well as for the reference sequence in the
ChIP reaction and input, according to [51,52]. Thus, a value of
1.0 on the y-axis in the figures corresponds to Histone H3
association, and thus inferred nucleosome occupancy equal to that
of the non-expressed reference region, except where normalized to
untreated samples.
RNA was prepared from corresponding 15 mL culture aliquots
by adding Ethanol to 70%, then flash freezing the cell suspension
in liquid nitrogen, and storing at 280uC for processing. RNA was
isolated from frozen cell pellets by extraction with hot acid phenol,
followed by precipitation through 5.7 M CsCl modified from [53].
Gene expression was analyzed by RT-qPCR, using randomly
primed MMLV-RT (Promega) cDNA synthesis reactions contain-
ing 1 mg RNA. SYBR-Green containing qPCR reactions with 1/
200th dilution of the RT reaction and using gene-specific primers
(see Table S2) in a Lightcycler LC480 (Roche) were then
quantified using pooled cDNA dilutions to generate standard
curves as for the ChIP analysis [54]. Levels of PDR gene
expression were compared between samples by normalizing each
signal to the RPR1 internal reference transcript, or in certain
indicated experiments to the RDN25 or the SCR1 internal
reference.
Results
The Pdr1 transcription factor interacts with Gal11 and
FACT
In order to identify proteins interacting with the Pdr1
transcriptional activator, we used the Pdr1 activation domain
immobilized as a GST fusion protein for affinity chromatography,
potentially bypassing any xenobiotic binding requirement on the
activation domain. Specifically bound proteins eluting from the
matrix were identified by mass spectrometry, and included both
the Spt16 and Pob3 subunits of FACT, as well as the Gal11
subunit of Mediator (Fig. S1). We have previously shown that the
KIX domain of Gal11 interacts with Pdr1, and that gal11
mutations diminish the PDR response [22]. Notably, mutations in
some other Mediator components did not have this same effect
[23]. Thus, identification in parallel of a known Pdr1-interacting
factor necessary for PDR response serves as a positive control for
the FACT-Pdr1 association, and suggests that recovery of FACT is
physiologically significant.
FACT mutations affect antifungal sensitivity, and are
additive with Mediator mutations
FACT has been shown to play a role in transcriptional
activation at promoters [37,46,47] and to interact directly with
the transcription factor SBF [55]. The Pdr1 – FACT interaction
might also be direct, or it could involve intermediary bridging
factors. Consistent with the latter possibility, we were unable to
effectively co-immunoprecipitate Pdr1 with FACT. Previous work
has shown that gal11 mutations confer sensitivity to xenobiotic
drugs [22], so to test the relevance of FACT in PDR gene
activation we asked whether FACT mutations have a similar effect
by plating serial dilutions onto plates containing ketoconazole, an
antifungal drug and inducer of PDR gene expression reviewed in
[2,56]. The FACT mutants show some growth defect in the
presence of ketoconazole, and the FACT gal11 double mutants
show a significant additive growth defect (Fig. 1). This suggests that
Gal11 and FACT act in parallel on the same process in PDR.
PDR expression and Mediator recruitment respond
rapidly to antifungal exposure
PDR genes are expressed at modest levels in the absence of
exogenous xenobiotic agents, but are rapidly induced to high levels
following drug exposure (Fig. 2A and Fig. 3B) [17,22]. In order to
more precisely characterize the role of Gal11 in PDR gene
activation, we treated logarithmically growing cells, wild type and
gal11mutants, with high dose (40 mM) ketoconazole, and harvested
samples periodically over 40 min for RNA analysis and for Gal11
ChIP to measure Mediator recruitment. We observed a marked
defect in the normally rapid PDR gene induction in gal11 mutant
strains (Fig. 2A) and a similar defect in multiple FACTmutants with
different growth conditions (Fig. S2 and Fig. S3). ChIP experiments
show Gal11 is rapidly recruited to the PDR promoters following
ketoconazole exposure (Fig. 2B), with the kinetics of Gal11 binding
roughly correlatingwith gene activation.These experiments support
the idea that both Gal11 and FACT are required for PDR gene
activation, with the kinetics of Mediator recruitment suggesting a
direct role in activation.
Transcriptional response and histone occupancy of PDR
genes is rapid and dynamic
In order to understand the role of FACT and chromatin in the
PDR response, we first analyzed nucleosome occupancy by using
Histone H3 ChIP assays in the promoter and coding regions in the
absence of toxin treatment. For our chromatin studies we focused
on the canonical Pdr1 target PDR5, encoding a prominent drug
efflux pump, and determined H3 binding in the uninduced state.
We used five sets of PCR primers, for the far upstream region, two
parts of the Upstream Activating Region (UAS-L and UAS-R), the
TATA region, and within the transcribed ORF (see diagram in
Fig. 3C). The ChIP experiments in Fig. 3A clearly show that the
PDR5 UAS is within a Nucleosome Depleted Region (NDR),
consistent with whole-genome analyses of histone occupancy [57–
59]. (As described in Methods, for all histone H3 ChIP assays a
value of 1 on the y-axis corresponds to the inferred nucleosome
occupancy seen at a gene-free reference region on chromosome I.).
Repopulation of Nucleosomes by FACT
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We first analyzed the kinetics of the transcriptional response and
changes in chromatin structure in wild type cells grown at the
standard temperature of 30uC. Cells were treated with ketoconazole
and samples were taken periodically over 60 minutes for both RNA
analysis and for histone H3 ChIP to measure nucleosome
occupancy. RT-qPCR was used to measure mRNA levels for five
genes of the PDR regulon, including PDR5, and the results show
rapid induction, visible at the first time point (5 min), a peak at 15 to
25 min, and a return to baseline at 40 to 50 min (Fig. 3B).
Normalizing the data for each gene to transcript levels in untreated
cells, induction levels of 4 to 16 fold are seen.
The time course ChIP experiments (Fig. 3D) show an
immediate depletion of histones at 5 min following drug addition
in the TATA and ORF regions, and even within the UAS which
contains sufficiently low histone occupancy to be described as an
NDR. Surprisingly, this histone loss is also seen upstream of the
UAS, suggesting that effects on chromatin from drug binding by
the Pdr1 factor can be propagated bi-directionally. After the initial
rapid loss, histone H3 signal begins to return to the upstream
regions first, with detectable repopulation by 10 minutes, while the
signal remains transiently depleted across the entire promoter and
transcription unit. Nucleosome loss across the promoter and
coding region persists until about 25 minutes, and returns to the
full basal occupancy conditions at 40 to 50 minutes, even though
drug is still present. Note that nucleosome binding is inversely
correlated with PDR5 transcription.
Altered chromatin dynamics at PDR5 in FACT mutant
strains
We next asked how FACT defects affect the dynamics of
chromatin alterations at PDR genes during activation and
repression. Most FACT mutations are temperature sensitive for
growth [31], and many studies, including those in Fig. S2, utilize a
temperature shift protocol in order to reveal FACT defects.
However, such procedures also induce a heat shock response, and
Figure 1. Mutations in FACT sensitize cells to the antifungal ketoconazole. A) Serial dilutions of DY150 (WT), DY5628 (gal11), DY6189
(spt16(G132D)), DY7230 (spt16-11), DY7379 (pob3(L78R)), or DY14202 (gal11 pob3(L78R)) were identically spotted onto YPAD agar plates lacking or
containing 200 or 500 nM ketoconazole, grown under the indicated conditions, and then photographed. B) Dilute cultures of DY150 (WT) and
DY8107 (spt16-11) were incubated in quadruplicate at the indicated temperatures in the absence or presence of 200 nM or 500 nM ketoconazole
while OD600 was measured at 30 min. intervals and plotted as a function of incubation time. Error bars indicate the SEM of the four duplicate culture
readings at each time point.
doi:10.1371/journal.pone.0084092.g001
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this will lead to activation of many PDR genes because most of
these genes, including PDR1 and PDR3, also contain binding sites
for the heat shock-induced Hsf1 and/or Yap1 factors adjacent to
the Pdr1 binding sites [60,61] (also see Fig. 3C). For this reason we
wanted to avoid a sudden change in temperature in our studies.
To this end, growth curves were generated for wild type and spt16-
11 (aa T828I, P859S) mutant strains grown continuously in liquid
culture at various temperatures in the presence and absence of
ketoconazole (Fig. 1B). At the semi-permissive temperature of
36uC the spt16-11 mutant grows very poorly, while at 34uC the
spt16-11 strain displays relatively normal growth characteristics in
the absence of added drug. We decided to use the spt16-11 mutant
grown at 34uC in subsequent experiments; importantly, under
these conditions ketoconazole inhibits growth in a dose-dependent
manner (Fig. 1B, middle panel). In our experiments, the wild type
and spt16-11 strains were cultivated at 34uC continuously for at
least 12 hours to attain mid-log density before addition of drug,
allowing temperature adaptation and thus avoiding any heat shock
effects.
We first studied wild type and spt16-11 mutant cells grown at
34uC in the absence of drug, measuring PDR5 mRNA levels by
RT-qPCR and examining PDR5 chromatin architecture by
histone H3 ChIP. Basal expression of PDR5 is reduced about 3-
fold in the spt16-11 mutant (Fig. 4B). Similar mild reductions are
seen at several other PDR genes in spt16-11 (e.g., PDR16 and
SNQ2) and with several other mutant FACT alleles (Fig. S2 and
Fig. S3), indicating this effect is not FACT allele-specific, nor due
to the normalization methods. Chromatin structure at PDR genes
in wild type cells at 34uC is similar (Fig. 4C) to that seen at 30uC
(Fig. 3A), as evidenced by histone H3 ChIP signals. In spt16-11
cells at 34uC, the NDR is still present at the PDR5 promoter, but
the histone H3 ChIP signals in more highly occupied locations are
somewhat reduced (Fig. 4C), suggesting FACT-dependent alter-
ations to chromatin architecture in the absence of toxin. To
determine whether the nucleosome occupancy levels at PDR5 are
directly due to FACT, Spt16 ChIPs were performed in uninduced
wild type or spt16-11 cells (Fig. 4D). FACT occupancy mirrors that
of nucleosomes at this gene, with Spt16 ChIP signals relatively
increased at those locations with higher histone H3 ChIP signals,
but with signals at or below background levels in the NDR region
of the PDR5 UAS. To address the specificity of the Spt16 ChIP
signals, the spt16-11 negative control ChIP (Fig. 4D, open bars)
was performed because the specific enrichment of wild type FACT
at any particular gene relative to control is usually mild, probably
due to FACT binding activity throughout the genome. Inactive
mutant FACT protein levels are probably quite reduced at this
semi-permissive temperature in mutant cells, based on the reduced
levels seen in Western blots at the non-permissive temperature of
37uC [62], and loss of FACT function under these conditions has
been observed in other assays [63]. The low enrichment values for
FACT binding across PDR5 in the spt16-11 strain grown at 34uC
thus define ChIP background signals. However, the small
reductions from loss of FACT binding and function in both
expression (,3-fold) and histone occupancy in non-drug treated
cells are unlikely to account for the observed defects in the PDR
phenotype.
To address the hypothesis that the effects of FACT loss are
more important to dynamic changes in PDR induction upon drug
Figure 2. PDR genes are rapidly induced by drug treatment, in a Gal11 dependent process. A) RT-qPCR analysis of several PDR gene RNAs
from ketoconazole treated cultures of gal11 and FACT mutant strains: DY6129 (WT, black lines) vs. DY4257 (gal11, red lines) were grown to mid-log
density at 25uC, temperature shifted to 37uC for 1 hr, 40 mM ketoconazole was added, and then samples were taken at the indicated times. RNA was
isolated and RT-qPCR performed using primers targeting the transcribed regions of PDR5, PDR16, SNQ2, and YOR1, with results plotted as fold relative
to the RDN25 reference transcript. B) ChIP with anti-Myc antibodies directed against C-terminally Myc tagged Gal11, from the same DY 6129 (WT)
cultures as in A, using primers targeting the full UAS regions of several PDR genes encompassing the PDRE sequences for PDR5, PDR16, SNQ2, and
YOR1. ChIP signals are expressed as fold enrichment relative to the intergenic IGR-I reference target, and are normalized to non drug-treated samples.
Error Bars represent the SD of three replicate qPCR reactions. Data presented are representative of two to three independently replicated
experiments. See Table S2 for primer sequences.
doi:10.1371/journal.pone.0084092.g002
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exposure rather than basal expression, we next added 40 mM
ketoconazole to wild type and spt16-11 cells grown continuously at
34uC. PDR5 mRNA was measured by RT-qPCR (Fig. 5B) and
histone H3 occupancy across PDR5 was assayed by ChIP (Fig. 5C),
over a longer period and with more frequent sampling for finer
resolution. PDR5 induction occurs somewhat faster in wild type
cells at this temperature. Importantly, the amplitude of PDR5
RNA accumulation and the rate of increase were both lowered in
the spt16-11 strain (Fig. 5B), and similar reductions and delays
were also seen at other PDR genes (Fig. S3, which also includes the
same data from Fig. 5B for comparison), with the time of peak
mRNA abundance delayed by at least 10 min relative to WT. The
transcription of PMA1, encoding the membrane H+ ATPase
required for PDR, but not regulated by Pdr1, [64,65] did not show
a similar profile of FACT-dependent induction, indicating that this
burst of transcription is not a general response (Fig. S3). Time
course gene expression experiments with the other mutant FACT
alleles also show defects in PDR gene induction in response to
xenobiotic drugs (Fig. S2). In contrast, a gal11 mutation affecting
Mediator function causes a much more severe defect in PDR gene
induction (Fig. 2A) [22].
Histone H3 chromatin binding measurements upon ketocona-
zole induction throughout the PDR5 promoter and ORF were
then undertaken. These time course experiments showed a rapid
loss of histone H3 ChIP signal upon ketoconazole addition in the
upstream, TATA and ORF regions, with minimum occupancy at
2.5 to 5 min after drug treatment in wild type cells (Fig. 5C).
Importantly, this rapid loss was observed in both wild type and
spt16-11 cells, notwithstanding the transcriptional induction
defects observed in spt16-11 at the same time, although there
may be a slightly delayed eviction in the absence of FACT. This
analysis concluded that nucleosome occupancy was rapidly
restored to pre-induction levels in wild type cells. However,
although FACT mutants exhibited nucleosome loss with kinetics
similar to wild type cells, the spt16-11 mutant exhibited a marked
defect in the ability to repopulate chromatin to the pre-induction
level of histone occupancy compared to wild type. Histone H3
association was still deficient 60 min following drug addition in the
Figure 3. Nucleosome depletion and re-deposition across PDR5 during induction by exposure to ketoconazole. A) Histone H3 ChIP was
used to measure nucleosome occupancy at the indicated regions relative to the gene-free IGR-I region across the PDR5 promoter and ORF in a DY150
(WT) strain grown @ 30u, using these primers: PDR5 Upstream (F2710- F2711), PDR5 UAS-L (primers F2460- F2712), PDR5 UAS-R (primers F3229-
F3230), PDR5 TATA (primers F2488-F2489), and PDR5 ORF (primers F3198-F3199). Error Bars represent the SD for three biological replicate cultures.
Results show the relatively depleted region encompassing the Pdr1 and Yap1 binding sites in the promoter as shown in C, with higher occupancy
elsewhere. B) RT-qPCR analysis of several PDR gene RNAs (using PDR5, PDR15, PDR16, SNQ2, and YOR1 ORF primer sets) from DY150 (WT) cells treated
with a 60 min. timecourse of ketoconazole, plotted as fold relative to the RPR1 reference transcript. Gene expression was normalized to the basal
levels prior to treatment. Error Bars represent the data range of duplicate RT and qPCR reactions. C) Diagram of the PDR5 promoter and ORF, showing
relative positions of nucleosomes (ovals) based on data from [57–59], PDRE (potential Pdr1 binding sites) and Yap1 sites, the TATA, TSS, and ATG, and
PCR target amplicons. D) Histone H3 ChIP was used to measure nucleosome loss and re-deposition at the indicated regions relative to IGR-I across
PDR5 just before and at intervals for 1 hour after addition of ketoconazole to DY150 (WT) cultures. Values are calculated as in A. Error Bars represent
the SD of three replicate qPCR reactions. Data presented in 3B and 3C are typical of experiments independently repeated at least six times. See
Table S2 for primer sequences.
doi:10.1371/journal.pone.0084092.g003
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FACT mutant, while in wild type, nucleosomes were fully
repopulated by 30 min. This same overall pattern of nucleosome
binding dynamics is reproducibly seen for several genes in the PDR
regulon (Fig. S4).
ChIPs were performed with anti-Spt16 antibody to measure
FACT recruitment to PDR5 during the time course described for
Fig. 5B and 5C. As shown in Fig. 5D, there is a low amount of
FACT binding to the ORF before induction, but FACT
occupancy increases during the initial chromatin disassembly
phase that accompanies gene induction (10 min). Substantially
more FACT binding is seen after gene expression has ended,
coinciding with the time of nucleosome repopulation (30 min).
Relatively little FACT is recruited to the NDR region at the UAS.
Discussion
Transcriptional activation of the PDR genes is unusual because
the Pdr1 transcription factor is always promoter-bound, even in
the absence of inducers. Upon binding to xenobiotic agents the
large carboxyl-terminal domain harboring the activation domain
of Pdr1 changes in unknown ways to facilitate gene activation.
This transcriptional response requires the Gal11 subunit of
Mediator, and here we show that there is rapid recruitment of
Gal11 to PDR gene promoters coincident with the sudden burst of
gene activation.
Mass spectroscopy of Pdr1 interacting proteins detected the Spt16
and Pob3 subunits of the FACT chromatin reorganizing complex,
and we find that FACT affects PDR gene expression in unexpected
ways. FACT mutants show an increased sensitivity to xenobiotic
drugs and a decrease in both basal and induced PDR gene
expression. At some promoters, sequence-specific DNA-binding
factors recruit FACT, which can then facilitate nucleosome eviction
at promoters as a prelude to gene activation [46,47,66].We expected
a similar scenario at thePDR genes.However, the promoters of these
genes have regions spanning the PDREs that are already largely
nucleosome free without stimulation, in addition to constitutive
occupancy by Pdr1, and thus the promoters do not require
nucleosome eviction before their rapid transcriptional response.
We could not detect additional FACT recruited to PDR gene control
elements during induction, possibly due to the reduced presence of
its nucleosomal substrate there, but only to transcribed regions,
consistent with FACT’s proposed roles in elongation. Further work
is needed to determine if the FACT binding signals observed in the
proximal promoter TATA region of PDR5 could be distinct from
that in the elongation region, or is a limitation of the resolution of the
ChIP assay. It is notable that FACT is recruited to the ORF in two
phases: The first coincides with nucleosome loss as transcription is
induced, and the second phase occurs concurrent with nucleosome
reassembly following conclusion of transcription. This biphasic
profile of recruitment is similar to that seen atCLN genes during cell-
Figure 4. spt16-11 alters histone binding across PDR5. A) Diagram of PDR5 as in Fig. 3. B) RT-qPCR analysis of PDR5 RNA from non-drug treated
DY150 (WT, filled bars) or DY8107 (spt16-11, open bars) cells, both grown at 34u and normalized to RPR1 reference transcripts, and plotted relative to
WT levels. C) ChIP analysis using antibodies against histone H3 at the indicated locations in PDR5 from the same non-drug treated WT or spt16-11
strains as above, normalized to an intergenic region on chromosome I (IGR-I) as a reference control. D) ChIP analysis using antibodies against Spt16
similarly to C. For all graphs, error bars represent the SD for three biological replicate cultures.
doi:10.1371/journal.pone.0084092.g004
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cycle induction in G1 [55]. The major defect observed in FACT
mutants at PDR genes was a marked delay in repopulation of
nucleosomes after transcription ceases in this second phase.
This defect in nucleosome repopulation is consistent with
FACT’s proposed roles in both nucleosome disassembly and
reassembly [29]. FACT mutant phenotypes of cryptic promoter
activation [40,43], failure to rebuild properly repressive chromatin
[67], and enhanced rates of histone replacement [68] support
models in which FACT is required for nucleosome reassembly.
Experiments presented in this work were carried out such that the
rapid kinetics of the PDR gene response were able to be measured,
and moreover the effects of FACT on the dynamic processes of
nucleosome disassembly and reassembly during a natural cycle of
induction and resolution could be directly observed in chromatin
composed of WT histones at native levels of abundance, in
contrast to previous approaches. Most surprisingly, FACT
mutations reduce both basal expression of PDR genes as well as
the rate of gene induction, even though chromatin looks normal in
the gene promoter. Why does a failure to reassemble nucleosomes
over PDR genes lead to reduced gene expression and a drug
resistance defect, rather than to a derepressed transcriptional
status? While there is a somewhat delayed return to uninduced
levels at some PDR genes in FACT mutant cells, it seems likely that
the observed transcriptional defects in FACT mutants are
probably due to aberrant reassembly of chromatin following
DNA replication in drug-free cells, as the PDR genes have not
been induced for many generations in our experimental setup.
Further analysis of the role of FACT in determining the nature of
PDR gene chromatin will be required.
PDR in fungi, and MDR more generally, occur in pathogenic
conditions and must be managed for successful clinical outcomes.
Understanding the roles of coactivators and modifiers of chroma-
tin at ABC transporter genes define prominent molecular targets,
which may allow the design of adjunct drug therapies targeting
these proteins that would inhibit resistance to antifungals or
chemotherapeutics. Moreover, drugs which interfere with factors
that modify chromatin, with FACT among them, have been
explored as chemotherapeutic agents [69,70], however these may
have unintended consequences for altering ABC gene expression,
both by activating MDR, as well as interfering with chromatin
regulators at those genes, and therefore enhancing resistance in
unexpected ways. A thorough understanding of all factors involved
in MDR gene regulation will allow rational intervention design to
clinically manage this phenomenon.
Supporting Information
Figure S1 Yeast FACT and Gal11 bind to the Pdr1
activation domain.
(PDF)
Figure 5. Kinetics of induction and nucleosome re-deposition at PDR5 correspond to FACT occupancy, and are defective in a FACT
mutant. DY5699 (WT, black lines) and DY8107 (spt16-11, red lines) cultures were grown at 34uC and treated with ketoconazole, with samples
collected every 2.5, 5, or 10 min. for ChIP and RNA during 60 minutes of exposure. RNA (5B) and ChIP (5C and 5D) analyses were as in Fig. 3 and
Fig. 4, at locations in PDR5 shown in 5A. C) H3 ChIP across PDR5 during drug induction, showing rapid nucleosome loss and differences in
repopulation. D) Chromatin samples from the same collection as those in Fig. 5C were analyzed by ChIP using antibodies against Spt16 for FACT
recruitment to PDR5. Data are reported as Fold ChIP signal relative to the gene-free IGR-I region. Error bars represent the data range for two biological
replicate cultures.
doi:10.1371/journal.pone.0084092.g005
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Figure S2 Altered PDR5 expression kinetics observed in
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